Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 29,139 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Completed Phase 1Phase 2 Interventional Results available

Treg Modulation With CD28 and IL-6 Receptor Antagonists

NCT04066114
Conditions
Living-Donor Kidney Transplant, Kidney Transplant Recipients
Interventions
lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone, tocilizumab, Prednisone, everolimus, belatacept, mycophenolate mofetil, mycophenolic acid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more
Completed Phase 2 Interventional Results available

Pharmacological Ascorbate for Lung Cancer

NCT02420314
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Interventions
Tagraxofusp, Cladribine (CLAD), Cytarabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Conditions
Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer
Interventions
CX-2009
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemzar (Gemcitabine), TH-302
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
59
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 52 more
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT05116826
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab with chemotherapy, Pleur-XTM catheter placement
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Propranolol, Prazosin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Epidermolysis Bullosa
Interventions
Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1Phase 2 Interventional Results available

Secretin Infusion for Pain Due to Chronic Pancreatitis

NCT01265875
Conditions
Chronic Pancreatitis
Interventions
Human Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Hypertriglyceridemia
Interventions
Diazoxide choline
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
Interventions
MLN8054
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Interventions
BAFF CAR-T
Drug
Lead sponsor
Luminary Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Pain
Interventions
placebo, valdecoxib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
68
States / cities
Birmingham, Alabama • Northport, Alabama • Glendale, Arizona + 46 more
Conditions
Wheezing, Reactive Airway Disease, Mild Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
4 Years to 8 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
Conditions
Presbyopia
Interventions
AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, AGN-190584 vehicle, AGN-199201 + AGN-190584 Combination, AGN-199201 vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 50 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Artesia, California • Azusa, California • Costa Mesa, California + 17 more